<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446781</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-303</org_study_id>
    <nct_id>NCT03446781</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women</brief_title>
  <acronym>RELEASE-2</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be screened for study eligibility within 14 days prior to enrolling in this&#xD;
      study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of&#xD;
      cellulite as independently assessed by the subject using the Patient Reported Photonumeric&#xD;
      Cellulite Severity Scale (PR-PCSS) and by the Investigator using the Clinician Reported&#xD;
      Photonumeric Cellulite Severity Scale (CR-PCSS) will be eligible. The eligibility of the&#xD;
      buttocks will be confirmed on Day 1. Once the eligibility of the buttocks is confirmed,&#xD;
      subjects will be randomly assigned to a treatment group (EN3835 0.84 mg per buttock or&#xD;
      placebo) in a 1:1 ratio within an investigational site. Each subject will receive a treatment&#xD;
      course which consists of up to 3 treatment visits (sessions), separated by 21 days (ie, Days&#xD;
      1, 22, and 43). Each treatment visit will consist of 12 injections (0.3 mL per injection of&#xD;
      EN3835 0.07 mg/injection or placebo; 0.84 mg in 3.6 mL per buttock) in each of the two&#xD;
      buttocks for a total volume of 7.2 mL (1.68 mg). Selection of dimples to be treated in the&#xD;
      buttocks will be at the discretion of the Investigator. End of study will occur at study day&#xD;
      71.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-level Composite Responders for the Target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Proportion of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). A 2-level composite responder is defined as a participant with improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock. A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-level PR-PCSS Responders of the Target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-level PR-PCSS Responders of the Target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-level Composite Responders of the Target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-level Composite Responders of the Non-target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician -Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-level SSRS Responders</measure>
    <time_frame>Day 71</time_frame>
    <description>Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from &quot;0&quot; (Extremely Dissatisfied) to &quot;6&quot; (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied [4], Very Satisfied [5], or Extremely Satisfied [6]) with the appearance of the cellulite on her buttocks at Day 71.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR-CIS Total Score</measure>
    <time_frame>Day 71</time_frame>
    <description>Patient-Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from &quot;0&quot; (Not at all) to &quot;10&quot; (Extremely). The PR-CIS total score is the sum of individual item scores and can range from &quot;0&quot; to &quot;60&quot; with higher numbers reflecting a more negative impact from the cellulite. A responder is defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at evaluation time point. A negative change from baseline indicates an improvement in cellulite severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-level S-GAIS Responders of Target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from &quot;+3&quot; (Very Much Improved) to &quot;-3&quot; (Very Much Worse). Responders are defined as participants with ≥1-level improvement (Improved, Much Improved or Very Improved) in S-GAIS assessment of the Target Buttock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-level S-GAIS Responders of Target Buttock</measure>
    <time_frame>Day 71</time_frame>
    <description>Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from &quot;+3&quot; (Very Much Improved) to &quot;-3&quot; (Very Much Worse). Responders are defined as participants with ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR-PCSS Rating for the Target and Non-target Buttock by Visit</measure>
    <time_frame>Day 71</time_frame>
    <description>The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant's cellulite. The ratings range from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Satisfaction With Cellulite Treatment</measure>
    <time_frame>Day 71</time_frame>
    <description>A 1-level Subject Satisfaction Responder is defined as a participant who is at least satisfied (Satisfied [+1], or Very Satisfied [+2]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Antibody Positivity by Visit</measure>
    <time_frame>Day 1 - Day 71</time_frame>
    <description>Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Antibody Titer Levels by Visit</measure>
    <time_frame>Day 1 - Day 71</time_frame>
    <description>Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is &quot;&lt;10&quot;. Only seropositive participants are summarized.</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles</measure>
    <time_frame>Day 71</time_frame>
    <description>Q1 and Q4 are based on the ADA titer levels.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy (Cellulite)</condition>
  <arm_group>
    <arm_group_label>EN3835 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EN3835 0.84mg (Collagenase Clostridium Histolyticum)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN3835</intervention_name>
    <description>Collagenase clostridium histolyticum</description>
    <arm_group_label>EN3835 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign and date an informed consent agreement&#xD;
&#xD;
          2. Be a female ≥18 years of age&#xD;
&#xD;
          3. At Screening visit, have 2 bilateral buttocks with each buttock having:&#xD;
&#xD;
               1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and&#xD;
&#xD;
               2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)&#xD;
&#xD;
          4. At Day 1 visit, have 2 bilateral buttocks with each buttock having:&#xD;
&#xD;
               1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and&#xD;
&#xD;
               2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)&#xD;
&#xD;
          5. Be willing to apply sunscreen to the buttocks before each exposure to the sun while&#xD;
             participating in the study (ie, Screening through end of study)&#xD;
&#xD;
          6. Be judged to be in good health, based upon the results of a medical history, physical&#xD;
             examination, and laboratory profile at Screening&#xD;
&#xD;
          7. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test&#xD;
             before injection of study drug and be using a stable and effective contraception&#xD;
             method (eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin]&#xD;
             contraceptives, or double barrier method) for at least 1 menstrual cycle prior to&#xD;
             study enrollment and for the duration of the study; or be menopausal defined as 12&#xD;
             months of amenorrhea in the absence of other biological or physiological causes, as&#xD;
             determined by the Investigator; or post-menopausal for at least 1 year; or be&#xD;
             surgically sterile&#xD;
&#xD;
          8. Be willing and able to cooperate with the requirements of the study&#xD;
&#xD;
          9. Be able to read, complete and understand the patient-reported outcomes rating&#xD;
             instruments in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has any of the following systemic conditions:&#xD;
&#xD;
               1. Coagulation disorder&#xD;
&#xD;
               2. Evidence or history of malignancy (other than excised basal-cell carcinoma)&#xD;
                  unless there has been no recurrence in at least 5 years&#xD;
&#xD;
               3. History of keloidal scarring or abnormal wound healing&#xD;
&#xD;
               4. Concurrent diseases or conditions that might interfere with the conduct of the&#xD;
                  study, confound the interpretation of the study results, or endanger the&#xD;
                  subject's well-being. Any questions about concurrent diseases should be discussed&#xD;
                  with the Medical Monitor&#xD;
&#xD;
               5. Evidence of clinically significant abnormalities on physical examination, vital&#xD;
                  signs, electrocardiogram (ECG), or clinical laboratory values&#xD;
&#xD;
          2. Has any of the following local conditions in the areas to be treated:&#xD;
&#xD;
               1. History of lower extremity thrombosis or post-thrombosis syndrome&#xD;
&#xD;
               2. Vascular disorder (eg, varicose veins, telangiectasia) in area to be treated&#xD;
&#xD;
               3. Inflammation or active infection&#xD;
&#xD;
               4. Severe skin laxity, flaccidity, and/or sagging&#xD;
&#xD;
               5. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer&#xD;
&#xD;
               6. Has a tattoo and/or a mole located within 2 cm of the site of injection&#xD;
&#xD;
          3. Requires the following concomitant medications before or during participation in the&#xD;
             trial:&#xD;
&#xD;
             a. Anticoagulant or antiplatelet medication or has received anticoagulant or&#xD;
             antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before&#xD;
             injection of study drug&#xD;
&#xD;
          4. Has used any of the following for the treatment of EFP on a buttock within the&#xD;
             timelines identified below or intends to use any of the following at any time during&#xD;
             the course of the study:&#xD;
&#xD;
               1. Liposuction in a buttock during the 12-month period before injection of study&#xD;
                  drug&#xD;
&#xD;
               2. Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment;&#xD;
                  buttock implant treatment; cryolipolysis; or surgery (including subcision and/or&#xD;
                  powered subcision) within a buttock during the 12-month period before injection&#xD;
                  of study drug&#xD;
&#xD;
               3. Any investigational treatment for EFP on a buttock during the 12-month period&#xD;
                  before the injection of study drug&#xD;
&#xD;
               4. Endermologie or similar treatments within a buttock during the 6-month period&#xD;
                  before injection of study drug&#xD;
&#xD;
               5. Massage therapy within a buttock during the 3-month period before injection of&#xD;
                  study drug&#xD;
&#xD;
               6. Creams (eg, Celluvera™, TriLastin®) and/or home therapies to prevent or mitigate&#xD;
                  EFP within a buttock during the 2-week period before injection of study drug&#xD;
&#xD;
          5. Is presently nursing or providing breast milk&#xD;
&#xD;
          6. Intends to become pregnant during the study&#xD;
&#xD;
          7. Intends to initiate an intensive sport or exercise program during the study&#xD;
&#xD;
          8. Intends to initiate a weight reduction program during the study&#xD;
&#xD;
          9. Intends to use tanning spray or tanning booths during the study&#xD;
&#xD;
         10. Has received an investigational drug or treatment within 30 days before injection of&#xD;
             study drug&#xD;
&#xD;
         11. Has a known systemic allergy to collagenase or any other excipient of study drug&#xD;
&#xD;
         12. Has received any collagenase treatments at any time prior to treatment&#xD;
&#xD;
         13. Was a subject in a previous cellulite clinical trial of CCH: AUX-CC-830, AUX-CC-831,&#xD;
             EN3835-102, EN3835-104, EN3835-201, EN3835-202, and/or EN3835-205&#xD;
&#xD;
         14. Any other condition(s) that, in the Investigator's opinion, might indicate the subject&#xD;
             to be unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McLane</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #4</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #5</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #6</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #7</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #8</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #9</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #10</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #11</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #12</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #13</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #14</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #15</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #16</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #17</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #18</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #19</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #20</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #21</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #22</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #23</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #24</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #25</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 4, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <results_first_submitted>August 5, 2020</results_first_submitted>
  <results_first_submitted_qc>September 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <disposition_first_submitted>September 26, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 15, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 8, 2020</disposition_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03446781/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Collagenase Clostridium Histolyticum (CCH)</title>
          <description>CCH 0.84 mg/Buttock 1.68 mg Total Dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo-control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Collagenase Clostridium Histolyticum (CCH)</title>
          <description>CCH 0.84 mg/Buttock 1.68 mg Total Dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo-control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="10.62"/>
                    <measurement group_id="B2" value="45.7" spread="11.16"/>
                    <measurement group_id="B3" value="46.7" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.52" spread="6.184"/>
                    <measurement group_id="B2" value="31.14" spread="7.567"/>
                    <measurement group_id="B3" value="30.82" spread="6.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Category (Fitzpatrick Scale)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I (Pale White)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II (Fair)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III (Darker White)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IV (Light Brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>V (Brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>VI (Dark Brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>2-level Composite Responders for the Target Buttock</title>
        <description>Proportion of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). A 2-level composite responder is defined as a participant with improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock. A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder.</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>2-level Composite Responders for the Target Buttock</title>
          <description>Proportion of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe). A 2-level composite responder is defined as a participant with improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock. A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder.</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-level PR-PCSS Responders of the Target Buttock</title>
        <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>1-level PR-PCSS Responders of the Target Buttock</title>
          <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-level PR-PCSS Responders of the Target Buttock</title>
        <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>2-level PR-PCSS Responders of the Target Buttock</title>
          <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-level Composite Responders of the Target Buttock</title>
        <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>1-level Composite Responders of the Target Buttock</title>
          <description>Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-level Composite Responders of the Non-target Buttock</title>
        <description>Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician -Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>2-level Composite Responders of the Non-target Buttock</title>
          <description>Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician -Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-level SSRS Responders</title>
        <description>Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from &quot;0&quot; (Extremely Dissatisfied) to &quot;6&quot; (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied [4], Very Satisfied [5], or Extremely Satisfied [6]) with the appearance of the cellulite on her buttocks at Day 71.</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock (1.68 mg Total Dose)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>1-level SSRS Responders</title>
          <description>Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from &quot;0&quot; (Extremely Dissatisfied) to &quot;6&quot; (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied [4], Very Satisfied [5], or Extremely Satisfied [6]) with the appearance of the cellulite on her buttocks at Day 71.</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR-CIS Total Score</title>
        <description>Patient-Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from &quot;0&quot; (Not at all) to &quot;10&quot; (Extremely). The PR-CIS total score is the sum of individual item scores and can range from &quot;0&quot; to &quot;60&quot; with higher numbers reflecting a more negative impact from the cellulite. A responder is defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at evaluation time point. A negative change from baseline indicates an improvement in cellulite severity.</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock (1.68 mg Total Dose)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR-CIS Total Score</title>
          <description>Patient-Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from &quot;0&quot; (Not at all) to &quot;10&quot; (Extremely). The PR-CIS total score is the sum of individual item scores and can range from &quot;0&quot; to &quot;60&quot; with higher numbers reflecting a more negative impact from the cellulite. A responder is defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at evaluation time point. A negative change from baseline indicates an improvement in cellulite severity.</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="8.01"/>
                    <measurement group_id="O2" value="51.6" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="13.57"/>
                    <measurement group_id="O2" value="45.1" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="12.74"/>
                    <measurement group_id="O2" value="-6.5" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>With factors of treatment group and analysis center adjusted for baseline values in the model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-level S-GAIS Responders of Target Buttock</title>
        <description>Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from &quot;+3&quot; (Very Much Improved) to &quot;-3&quot; (Very Much Worse). Responders are defined as participants with ≥1-level improvement (Improved, Much Improved or Very Improved) in S-GAIS assessment of the Target Buttock.</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>1-level S-GAIS Responders of Target Buttock</title>
          <description>Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from &quot;+3&quot; (Very Much Improved) to &quot;-3&quot; (Very Much Worse). Responders are defined as participants with ≥1-level improvement (Improved, Much Improved or Very Improved) in S-GAIS assessment of the Target Buttock.</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-level S-GAIS Responders of Target Buttock</title>
        <description>Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from &quot;+3&quot; (Very Much Improved) to &quot;-3&quot; (Very Much Worse). Responders are defined as participants with ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.</description>
        <time_frame>Day 71</time_frame>
        <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Clostridium Histolyticum (CCH)</title>
            <description>CCH 0.84 mg/Buttock</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-control</description>
          </group>
        </group_list>
        <measure>
          <title>2-level S-GAIS Responders of Target Buttock</title>
          <description>Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from &quot;+3&quot; (Very Much Improved) to &quot;-3&quot; (Very Much Worse). Responders are defined as participants with ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.</description>
          <population>ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCH 0.84 mg/Buttock versus Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for analysis center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PR-PCSS Rating for the Target and Non-target Buttock by Visit</title>
        <description>The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant's cellulite. The ratings range from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
        <time_frame>Day 71</time_frame>
        <population>mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and non-target buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 1: CCH</title>
            <description>Baseline (Day 1) for CCH Treated Group</description>
          </group>
          <group group_id="O2">
            <title>Day 1: Placebo</title>
            <description>Baseline (Day 1) for PlaceboGroup</description>
          </group>
          <group group_id="O3">
            <title>Day 22: CCH</title>
            <description>Day 22 for CCH Treated Group</description>
          </group>
          <group group_id="O4">
            <title>Day 22: Placebo</title>
            <description>Day 22 for Placebo Group</description>
          </group>
          <group group_id="O5">
            <title>Day 43: CCH</title>
            <description>Day 43 for CCH Treated Group</description>
          </group>
          <group group_id="O6">
            <title>Day 43: Placebo</title>
            <description>Day 43 for Placebo Group</description>
          </group>
          <group group_id="O7">
            <title>Day 71: CCH</title>
            <description>Day 71 for CCH Treated Group</description>
          </group>
          <group group_id="O8">
            <title>Day 71: Placebo</title>
            <description>Day 71 for Placebo Group</description>
          </group>
          <group group_id="O9">
            <title>Day 71: CCH (LOCF)</title>
            <description>Day 71 for CCH Treated Group (Last Observation Carried Forward)</description>
          </group>
          <group group_id="O10">
            <title>Day 71: Placebo (LOCF)</title>
            <description>Day 71 for Placebo Group (Last Observation Carried Forward)</description>
          </group>
        </group_list>
        <measure>
          <title>PR-PCSS Rating for the Target and Non-target Buttock by Visit</title>
          <description>The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant's cellulite. The ratings range from &quot;0&quot; (None) to &quot;4&quot; (Severe).</description>
          <population>mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and non-target buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="209"/>
                <count group_id="O6" value="201"/>
                <count group_id="O7" value="209"/>
                <count group_id="O8" value="201"/>
                <count group_id="O9" value="209"/>
                <count group_id="O10" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Target Buttock Rating</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="199"/>
                    <count group_id="O5" value="186"/>
                    <count group_id="O6" value="191"/>
                    <count group_id="O7" value="186"/>
                    <count group_id="O8" value="191"/>
                    <count group_id="O9" value="209"/>
                    <count group_id="O10" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost None (1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="61"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="64"/>
                    <measurement group_id="O10" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="85"/>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="76"/>
                    <measurement group_id="O9" value="76"/>
                    <measurement group_id="O10" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="101"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="77"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="81"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-target Buttock Rating</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="199"/>
                    <count group_id="O5" value="186"/>
                    <count group_id="O6" value="191"/>
                    <count group_id="O7" value="186"/>
                    <count group_id="O8" value="191"/>
                    <count group_id="O9" value="209"/>
                    <count group_id="O10" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost None (1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="55"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="58"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="64"/>
                    <measurement group_id="O10" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="86"/>
                    <measurement group_id="O7" value="66"/>
                    <measurement group_id="O8" value="72"/>
                    <measurement group_id="O9" value="74"/>
                    <measurement group_id="O10" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="108"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="77"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="84"/>
                    <measurement group_id="O9" value="49"/>
                    <measurement group_id="O10" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Satisfaction With Cellulite Treatment</title>
        <description>A 1-level Subject Satisfaction Responder is defined as a participant who is at least satisfied (Satisfied [+1], or Very Satisfied [+2]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite.</description>
        <time_frame>Day 71</time_frame>
        <population>mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and non-target buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Day 71: CCH</title>
            <description>Day 71 for CCH Treated Group</description>
          </group>
          <group group_id="O2">
            <title>Day 71: Placebo</title>
            <description>Day 71 for Placebo Group</description>
          </group>
          <group group_id="O3">
            <title>Day 71: CCH (LOCF)</title>
            <description>Day 71 for CCH Treated Group (Last Observation Carried Forward)</description>
          </group>
          <group group_id="O4">
            <title>Day 71: Placebo (LOCF)</title>
            <description>Day 71 for Placebo Group (Last Observation Carried Forward)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Satisfaction With Cellulite Treatment</title>
          <description>A 1-level Subject Satisfaction Responder is defined as a participant who is at least satisfied (Satisfied [+1], or Very Satisfied [+2]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite.</description>
          <population>mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and non-target buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very Satisfied (+2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfied (+1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neither Satisfied Nor Dissatisfied (0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dissatisfied (-1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Dissatisfied (-2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Antibody Positivity by Visit</title>
        <description>Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit.</description>
        <time_frame>Day 1 - Day 71</time_frame>
        <population>Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-AUX-I: CCH</title>
            <description>Antibody AUX-I for the CCH Treated Group</description>
          </group>
          <group group_id="O2">
            <title>Anti-AUX-I: Placebo</title>
            <description>Antibody AUX-I for the Placebo Group</description>
          </group>
          <group group_id="O3">
            <title>Anti-AUX-II: CCH</title>
            <description>Antibody AUX-II for the CCH Treated Group</description>
          </group>
          <group group_id="O4">
            <title>Anti-AUX-II: Placebo</title>
            <description>Antibody AUX-II for the Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Antibody Positivity by Visit</title>
          <description>Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit.</description>
          <population>Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="214"/>
                    <count group_id="O4" value="206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Seropositive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seronegative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="204"/>
                    <measurement group_id="O3" value="211"/>
                    <measurement group_id="O4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Seropositive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seronegative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="198"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="190"/>
                    <count group_id="O3" value="186"/>
                    <count group_id="O4" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Seropositive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="183"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seronegative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="190"/>
                    <count group_id="O3" value="186"/>
                    <count group_id="O4" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Seropositive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seronegative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="182"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Antibody Titer Levels by Visit</title>
        <description>Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is &quot;&lt;10&quot;. Only seropositive participants are summarized.</description>
        <time_frame>Day 1 - Day 71</time_frame>
        <population>Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-AUX-I: CCH</title>
            <description>Antibody AUX-I for the CCH Treated Group</description>
          </group>
          <group group_id="O2">
            <title>Anti-AUX-I: Placebo</title>
            <description>Antibody AUX-I for the Placebo Group</description>
          </group>
          <group group_id="O3">
            <title>Anti-AUX-II: CCH</title>
            <description>Antibody AUX-II for the CCH Treated Group</description>
          </group>
          <group group_id="O4">
            <title>Anti-AUX-II: Placebo</title>
            <description>Antibody AUX-II for the Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Antibody Titer Levels by Visit</title>
          <description>Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is &quot;&lt;10&quot;. Only seropositive participants are summarized.</description>
          <population>Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.</population>
          <units>log 10 titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.235" spread="1.7365"/>
                    <measurement group_id="O2" value="1.000" spread="0.0000"/>
                    <measurement group_id="O3" value="3.212" spread="0.8056"/>
                    <measurement group_id="O4" value="1.365" spread="0.3834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.331" spread="1.2566"/>
                    <measurement group_id="O2" value="3.504"/>
                    <measurement group_id="O3" value="1.912" spread="1.2718"/>
                    <measurement group_id="O4" value="1.387" spread="0.4788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="183"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.602" spread="0.8721"/>
                    <measurement group_id="O2" value="2.539" spread="1.1462"/>
                    <measurement group_id="O3" value="3.680" spread="1.0617"/>
                    <measurement group_id="O4" value="1.302" spread="0.4596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.898" spread="0.7131"/>
                    <measurement group_id="O2" value="2.039" spread="1.2854"/>
                    <measurement group_id="O3" value="5.255" spread="0.7142"/>
                    <measurement group_id="O4" value="1.572" spread="0.7895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles</title>
        <description>Q1 and Q4 are based on the ADA titer levels.</description>
        <time_frame>Day 71</time_frame>
        <population>Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCH: Q1</title>
            <description>Q1 for the CCH Treated Group</description>
          </group>
          <group group_id="O2">
            <title>CCH: Q4</title>
            <description>Q4 for the CCH Treated Group</description>
          </group>
          <group group_id="O3">
            <title>CCH: Total</title>
            <description>Total CCH</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles</title>
          <description>Q1 and Q4 are based on the ADA titer levels.</description>
          <population>Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutralizing AUX-I Antibody</title>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing AUX-II Antibody</title>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All (serious and nonserious) AEs, from Day 1 to Day 71</time_frame>
      <desc>All (serious and nonserious) AEs, whether elicited or observed during study visits or spontaneously reported by the participant, including events that occurred from the time the participant signed the study-specific consent form until completion of or discharge from the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Collagenase Clostridium Histolyticum (CCH)</title>
          <description>CCH 0.84 mg/Buttock 1.68 mg Total Dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo-control</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saji Vijayan, MBBS</name_or_title>
      <organization>Endo Pharmaceuticals</organization>
      <phone>800-462-3636</phone>
      <email>ClinicalTrials@Endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

